About Walvax
Walvax is a company based in Kunming (China) founded in 2001. The company has 1,930 employees. Walvax operates in a competitive market with competitors including Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others.
- Headquarter Kunming, China
- Employees 1,930
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website walvax.com
- Social LinkedIn
- Legal Name Walvax Biotechnology Co., Ltd. Class A
- Annual Revenue$344.24 M (USD)-14.31as on Dec 31, 2025
- Net Profit$25.39 M (USD)25.03as on Dec 31, 2025
- EBITDA$68.81 M (USD)-1.36as on Dec 31, 2025
- Latest Funding Round$72.8M (USD), Post-IPO
Aug 2014
- Employee Count1,930
Funding Insights of Walvax
- Total Rounds 1
- Last Round Post-IPO — $72.8M
- First Round $72.8M
(Aug 2014)
All 1 funding rounds of Walvax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2014 | $72.8M | Post-IPO | – | – | – |
IPO & Listings of Walvax
Walvax is a publicly listed company on the SZSE with ticker symbol 300142 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Nov 2010
- Listed onSSE: 300142
- Listed entityWalvax Biotechnology Co., Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE100000WN2
- Share price14.05 CNY (-4.75% on the day) · 2026-10-12
- Market capitalisation23,329,139,911.00 CNY
- Price to earnings119.1
- EPS (diluted, trailing year)0.12 CNY
- Dividend yield1.05%
- Volume (last session)105,209,075
Financials of Walvax
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.41B CNY | 177.7M CNY | 481.7M CNY |
| 2024 | 2.81B CNY | 142.2M CNY | 488.4M CNY |
| 2023 | 4.09B CNY | 419.4M CNY | 987.2M CNY |
| 2022 | 5.07B CNY | 728.6M CNY | 1.39B CNY |
| 2021 | 3.44B CNY | 427.8M CNY | 976.8M CNY |
Detailed financial statements for Walvax
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Walvax
3 dated milestones of Walvax across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Walvax is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $72.8M.
Competitors of Walvax
Walvax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Serum Institute of India, Vaxcyte, HOOKIPA Pharma, Vir Biotechnology and Biological E, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| valneva.com | 1999 | Lyon, France | $113.55M | – | Prophylactic vaccines for infectious diseases are developed and advanced. | |
| anacor.com | 2002 | Palo Alto, United States | $90M | 110 | Developer of small-molecule therapeutics for the treatment of infectious and autoimmune diseases |
Detailed competitors of Walvax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Walvax
The website of Walvax (walvax.com) receives about 3K visits a month and ranks #5,013,364 among all websites worldwide, #5,803 in Biotechnology and Pharmaceuticals.
- Monthly visits3K
▼ 11.8% vs previous month
- Unique visitors1.3K
per month
- Global rank#5,013,364
among all websites
- Category rank#5,803
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.8
- Average visit38 sec
- DevicesDesktop 43% · Mobile 57%
Latest news on Walvax
Complete news archive for Walvax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Walvax
10 companies that operate in the same segment as Walvax (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Walvax
Walvax was founded in 2001 and raised its 1st funding round 13 years after it was founded.
Walvax is headquartered in Kunming, China. It is registered at Kunming, Yunnan, China.
Walvax has 1,930 employees.
Annual revenue of Walvax is $344.24M as on Dec 31, 2025.
Walvax was founded in 2001 in Kunming, China, as a vaccine manufacturer focused on the biopharmaceutical sector. Specialization is placed on developing and producing vaccines against meningitis and influenza. An in-house RD center is operated to support innovation. The company was listed publicly in November 2010, enabling expanded operations within the Chinese market and beyond.
Walvax's top competitors include Vaxcyte, HOOKIPA Pharma and Serum Institute of India.
Yes, Walvax is publicly traded on SZSE under the ticker symbol 300142.